Advanced search
Publication Cover
Biotechnology & Biotechnological Equipment Volume 28, 2014 - Issue 3
Submit an article Journal homepage
691
Views
0
CrossRef citations to date
0
Altmetric
Articles; Bioeconomics

Humanistic and economic aspects of haemophilia treatment in Bulgaria. Comparison between two therapeutic approaches: prophylactic vs. on-demand treatment

Guenka PetrovaFaculty of Pharmacy, Medical University of Sofia, Sofia, BulgariaCorrespondence[email protected]
View further author information
,
Konstantin TachkovFaculty of Pharmacy, Medical University of Sofia, Sofia, BulgariaView further author information
,
Svetla GeorgievaMedical University of Sofia, University Hospital ‘Alexandrovska’, Sofia, BulgariaView further author information
&
Maria DimitrovaFaculty of Pharmacy, Medical University of Sofia, Sofia, BulgariaView further author information
Pages 576-582 | Received 03 Feb 2014, Accepted 15 Mar 2014, Published online: 26 Aug 2014

References

  • Batorova A. Role of prophylaxis in joint protection – clinical, economical and quality of life aspects of prophylaxis vs on-demand treatment. Bratislava: National Hemophilia Center, Department of Hematology, University Hospital, Vilnius: Octapharma Academy; 2013.
  • Carlsson KS, Höjgård S, Lindgren A, Lethagen S, Schulman S, Glomstein A, Tengborn L, Berntorp E, Lindgren B. Costs of on-demand and prophylactic treatment for severe haemophilia in Norway and Sweden. Haemophilia. 2004;10(5):515–526.
  • De Waure C, Capri S, di Pietro ML, Kheiraoui F, Specchia ML, Capizzi S, Gualano MR, Nicolotti N, Sferrazza A, Cadeddu C, Veneziano MA, Di Nardo F, La Torre G, Ricciardi W. Assessment of the clinical and economic impact of Advate in prophylactic and treatment of hemophilia A patients. Italian J Public Health. 2012;9(4):Suppl 2:S1–S50.
  • Fischer K, Pouw ME, Lewandowski D, Janssen MP, van den Berg HM, van Hout BA. A modeling approach to evaluate long-term outcome of prophylactic and on demand treatment strategies for severe hemophilia A. Haematologica. 2011;96(5):738–743.
  • Johnson KA, Zheng-Yi Zhou. Costs of care in hemophilia and possible implications of health care reform. Hematology. 2011;2011:413–418.
  • Berntorp E, Boulyjenkov V, Brettler D, Chandy M, Jones P, Lee C, Lusher J, Mannucci P, Peak K, Rickard K, Seremetis S. Modern treatment of hemophilia. Bull World Health Organ. 1995;73(5):691–701.
  • Colvin BT, Astermark J, Fischer K, Gringeri A, Lassila R, Schramm W, Thomas A, Ingerslev J, Inter Disciplinary Working Group. European principles of haemophilia care. Haemophilia. 2008;14:361–374.
  • Den Uijl I, Biesma D, Grobbee D, Fischer K. Turning severe into moderate haemophilia by prophylaxis: are we reaching our goal? Blood Transfus. 2013;11:364–369.
  • Manco-Johnson M, Abshire T, Shapiro A, Riske B, Hacker MR, Kilcoyne R, Ingram JD, Manco-Johnson ML, Funk S, Jacobson L, Valentino LA, Hoots WK, Buchanan GR, DiMichele D, Recht M, Brown D, Leissinger C, Bleak S, Cohen A, Mathew P, Matsunaga A, Medeiros D, Nugent D, Thomas GA, Thompson AA, McRedmond K, Soucie JM, Austin H, Evatt BL. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N England J Med. 2007;357:535–544.
  • Noone D. What's the point to prophylaxis – long term survey. [ Internet]. Irish Haemophilia Society; 2010. Available from: https://www.haemophilia.ie/uploaded/Survey%20on%20ProphyDN%20AGM(2).pdf
  • Salinas-Escudero G, Galindo-Suarez Rosa María, Rely Kely, Carrillo-Vega María Fernanda, Muciño-Ortega Emilio. Cost-effectiveness analysis of prophylaxis vs. ‘on demand’ approach in the management in children with hemophilia A in Mexico. Bol Med Hosp Infant Mex. 2013;70(4):290–297.
  • Tagliaferri A, Di Perna C, Rivolta GF. Secondary prophylaxis in adolescent and adult hemophiliacs. Blood Transfus. 2008;6(Suppl 2):S17–S20.
  • Colombo G, Di Matteo S, Mancuso M, Santagostino E. Cost–utility analysis of prophylaxis versus treatment on demand in severe hemophilia A. Clin Econ Outcomes Res. 2011;3:55–61.
  • Gringeri A, Lundin B, von Mackensen S, Mantovani L, The ESPRIT Study Group. A randomized clinical trial of prophylaxis in children with hemophilia A. J Thromb Haemost, 2011;9:700–710.
  • Lindvall K, Von Mackensen S, Berntorp E. Quality of life in adult patients with haemophilia – a single centre experience from Sweden. Haemophilia. 2012; 18(4):527–531.
  • Feldman BM, Pai M, Rivard GE, Israels S, on behalf of the Association of Hemophilia Clinic Directors of Canada Prophylaxis Study Group. Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study. J Thrombosis Haemostasis. 2006;4:1228–1236.
  • Makris M. Prophylaxis in haemophilia should be life-long. Blood Transfus. 2012;10:165–168.
  • Peyvandi F. Haemophilia A versus haemophilia B: Similarities and differences: current approaches to prophylaxis. [ Internet]. University of Milan; 2012. Available from: http://www.ehc.eu/fileadmin/EHC-conference/2012/14-02_Ipsen-02_Flora_Peyvandi_-_Prophy_HB_final._Pfiser.pdf
  • Franchini M, Mannucci P. Prophylaxis for adults with haemophilia: towards a personalised approach? Blood Transfus. 2012;10:123–124.
  • Fischer K, Carlsson KS, Petrini P, Holmström M, Ljung R, van den Berg HM, Berntorp E. Intermediate-dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and cost since 1970s. Blood. 2013;122(7):1129–1136.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.